|Toxiciy Grade:||5||City/State/Province:||Rochester, NY|
|Treatments:||Chemotherapy, Hormone, Biologic therapy||Hospital:||University of Rochester School of Medicine and Dentistry|
This phase 2 study involved 49 previously untreated mantle cell lymphoma patients who. The median patient age was 57.4 years and 78% were male.
Patients were treated with a therapy regimen called hyperCVAD MTX/Ara-C and rituximab. This therapy consists of the chemotherapy agents cyclophosphamide, vincristine, doxorubicin, methotrexate, and cytarabine, the steroid hormone dexamethasone, and the biologic therapy agent rituximab (an antibody against the CD20 protein that helps the immune system attack cancer cells).
There was one treatment-related death due to infection. Grade 4 leukopenia and neutropenia was reported by 86% and 78% of patients, respectively. Grade 3 flu-like symptoms and grade 3-4 pain were also reported.
The median overall survival was 81.6 months.
Correspondence: Dr. Steven Bernstein; email: firstname.lastname@example.org